Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halobetasol Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.78 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.75 |
| ▸ | PPARG | P37231 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halobetasol Propionate SCHEMBL6006526 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL2849994 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL14518060 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL6753214 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL13321839 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL33858 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL10905947 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL17190306 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL10905949 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A | |
| Halobetasol Propionate SCHEMBL14339615 | 1.00 | PGR (1.00) | PGRARADORA3CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| US-4619921-A | Polyhalogeno-steroids | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | claimed |
| WO-2024227098-A1 | HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS | CITIUS PHARMACEUTICALS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-9365609-B2 | Process for preparing a crystalline form of halobetasol propionate | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2016-06-14 | — | — | US | disclosed |
| US-20130217903-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE | TARO PHARMACEUTICAL NORTH AMERICA, INC. (KY) | 2013-08-22 | — | — | US | disclosed |
| US-8361997-B2 | Process for preparing a crystalline form of halobetasol propionate | TARO PHARMACEUTICAL NORTH AMERICA, INC. (KY) | 2013-01-29 | — | — | US | disclosed |
| US-20100130760-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2010-05-27 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| US-20040138192-A1 | Crystalline forms of halobetasol propionate | CHEMAGIS LTD. (IL) | 2004-07-15 | — | — | US | disclosed |
| US-4619921-A | Polyhalogeno-steroids | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130760-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE | HSD3B1, HSD3B2, HSD11B2 | NR3C1 209/4885PGR 2552/4885AR 1084/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885PGR 965/4885AR 209/4885 |
| US-20130217903-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE | HSD3B1, HSD3B2, HSD11B2 | NR3C1 209/4885PGR 2552/4885AR 1084/4885 |
| US-20040138192-A1 | Crystalline forms of halobetasol propionate | HSD3B1, HSD3B2, CYP4B1 | NR3C1 551/4885PGR 3115/4885AR 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.